Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

3.980 -0.130 (-3.17%)
Streaming Delayed Price Updated: 9:52 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SELLAS Life Sciences Group, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗
Via Stocktwits
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Why Is SELLAS Life Sciences Stock Falling Today? ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗
Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B ↗
SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours. 
Via Stocktwits
Topics Death
News headline image
Why Is SLS Stock Drawing Significant Investor Attention Today? ↗
Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the... 
Via Stocktwits
Topics Death
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗
The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. 
Via Stocktwits
Topics Death
News headline image
SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗
Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 
Via Stocktwits
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗
The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest. 
Via Stocktwits
Topics Death
News headline image
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗
The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News ↗
Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams. 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin ↗
The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax. 
Via Stocktwits
News headline image
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment ↗
SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. 
Via Stocktwits
News headline image
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants ↗
In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of... 
Via Stocktwits
News headline image
SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges ↗
SELLAS Life Sciences (SLS) reported Q2 2025 EPS of -$0.07, beating estimates, with no revenue. Cash position strengthened to $25.3M. Clinical trials progress highlighted, including REGAL Phase 3 AML... 
Via Chartmill
News headline image
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Thursday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Top movers in Tuesday's after hours session ↗
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
What's going on in today's after hours session ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
SLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024 ↗
SLS stock results show that SELLAS Life Sciences Gr beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.